Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellectis S.A., a foreign private issuer, on December 29, 2020. The filing serves as a re-filing of specific exhibits originally submitted on Form F-1 in March 2015. The purpose is to transition to Regulation S-K Item 601(b) requirements, allowing the omission of confidential information from material contracts without a confidential treatment request.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding contract exhibits and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only change noted is the re-submission of the Exclusive Patent License Agreement with the Regents of the University of Minnesota (and its amendments) with certain confidential information redacted.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that specific information has been excluded from the attached exhibits because it is not material and would likely cause competitive harm if disclosed. The omitted portions are available to the SEC upon request.
Key Facts for Investor Verification
- The filing is administrative in nature, focusing on the redaction of confidential terms in patent license agreements.
- No financial data or operational updates are included in this specific report.
- Investors should refer to the company's Form 20-F or other periodic reports for financial performance and strategic outlook.
- The redacted information in the exhibits pertains to the Exclusive Patent License Agreement with the University of Minnesota.